GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » Cash Flow from Financing

Greenyn Biotechnology Co (ROCO:6846) Cash Flow from Financing : NT$192.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Greenyn Biotechnology Co received NT$0.4 Mil more from issuing new shares than it paid to buy back shares. It received NT$20.0 Mil from issuing more debt. It paid NT$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received NT$0.0 Mil from paying cash dividends to shareholders. It received NT$0.0 Mil on other financial activities. In all, Greenyn Biotechnology Co earned NT$20.4 Mil on financial activities for the three months ended in Mar. 2024.


Greenyn Biotechnology Co Cash Flow from Financing Historical Data

The historical data trend for Greenyn Biotechnology Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co Cash Flow from Financing Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
-46.02 -30.86 -90.98 -199.15 191.86

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.50 97.24 -12.29 89.42 17.89

Greenyn Biotechnology Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Greenyn Biotechnology Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Greenyn Biotechnology Co's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$192.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenyn Biotechnology Co  (ROCO:6846) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Greenyn Biotechnology Co's issuance of stock for the three months ended in Mar. 2024 was NT$0.4 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Greenyn Biotechnology Co's repurchase of stock for the three months ended in Mar. 2024 was NT$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Greenyn Biotechnology Co's net issuance of debt for the three months ended in Mar. 2024 was NT$20.0 Mil. Greenyn Biotechnology Co received NT$20.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Greenyn Biotechnology Co's net issuance of preferred for the three months ended in Mar. 2024 was NT$0.0 Mil. Greenyn Biotechnology Co paid NT$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Greenyn Biotechnology Co's cash flow for dividends for the three months ended in Mar. 2024 was NT$0.0 Mil. Greenyn Biotechnology Co received NT$0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Greenyn Biotechnology Co's other financing for the three months ended in Mar. 2024 was NT$0.0 Mil. Greenyn Biotechnology Co received NT$0.0 Mil on other financial activities.


Greenyn Biotechnology Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines